Abstract：
OBJECTIVE: The purpose of this study was to investigate the dynamic changes in serum (1-3)-β-D-glucan (BDG) caused by intravenous immunoglobulins (IVIG) infusion in adults.
METHODS: This study included patients who received IVIG infusion from October 2021 to October 2022 during hospitalization. We randomly examined two IVIG samples for every patient. Serum samples were collected at nine time points: before (Tpre), immediately (T1-0), 6h (T1-1) and 12h (T1-2) later on the first day; immediately (T2-0) and six hours later (T2-1) on the second day during IVIG infusion, and within three days after IVIG infusion (Ta1, Ta2, and Ta3, respectively). The Friedman test was used for statistical analysis.
RESULTS: A total of 159 serum BDG from 19 patients were included in the analysis. The BDG content of IVIG ranged from 249 pg/ml to 4812 pg/ml. Patients had significantly elevated serum BDG on T1-0 (176 (113, 291) pg/ml, p = 0.002) and Ta1 (310 (199, 470) pg/ml, p < 0.001), compared with Tpre (41 (38, 65) pg/ml). The increments of serum BDG (ΔBDG) were associated with BDG concentration of IVIG (Spearman r = 0.59, p = 0.02). Individuals with abnormal renal function indexes showed higher serum ΔBDG values at Ta1 (403 (207, 484) pg/ml) than patients with normal renal function (172 (85, 316) pg/ml, p = 0.036).
CONCLUSIONS: Patients who received IVIG had significantly higher serum BDG values. Elevated BDG levels correlate with BDG content of IVIG and abnormal renal function indexes.
METHODS: This study included patients who received IVIG infusion from October 2021 to October 2022 during hospitalization. We randomly examined two IVIG samples for every patient. Serum samples were collected at nine time points: before (Tpre), immediately (T1-0), 6h (T1-1) and 12h (T1-2) later on the first day; immediately (T2-0) and six hours later (T2-1) on the second day during IVIG infusion, and within three days after IVIG infusion (Ta1, Ta2, and Ta3, respectively). The Friedman test was used for statistical analysis.
RESULTS: A total of 159 serum BDG from 19 patients were included in the analysis. The BDG content of IVIG ranged from 249 pg/ml to 4812 pg/ml. Patients had significantly elevated serum BDG on T1-0 (176 (113, 291) pg/ml, p = 0.002) and Ta1 (310 (199, 470) pg/ml, p < 0.001), compared with Tpre (41 (38, 65) pg/ml). The increments of serum BDG (ΔBDG) were associated with BDG concentration of IVIG (Spearman r = 0.59, p = 0.02). Individuals with abnormal renal function indexes showed higher serum ΔBDG values at Ta1 (403 (207, 484) pg/ml) than patients with normal renal function (172 (85, 316) pg/ml, p = 0.036).
CONCLUSIONS: Patients who received IVIG had significantly higher serum BDG values. Elevated BDG levels correlate with BDG content of IVIG and abnormal renal function indexes.
摘要：
目的：本研究的目的是研究成年人静脉注射免疫球蛋白（IVIG）引起的血清（1-3）-β-D-葡聚糖（BDG）的动态变化。
方法：本研究包括2021年10月至2022年10月住院期间接受IVIG输注的患者。我们随机检查了每位患者的两个IVIG样品。在九个时间点收集血清样品：前（Tpre），立即（T1-0），第一天后6h（T1-1）和12h（T1-2）；在IVIG输注期间，第二天立即（T2-0）和六小时后（T2-1），和IVIG输注后三天内（分别为Ta1，Ta2和Ta3）。采用Friedman检验进行统计分析。
结果：共有来自19例患者的159份血清BDG纳入分析。IVIG的BDG含量范围为249μg/ml至4812μg/ml。患者在T1-0时血清BDG显着升高（176（113，291）pg/ml，p=0.002）和Ta1（310（199，470）pg/ml，p<0.001)，与Tpre（41（38，65）pg/ml）相比。血清BDG（ΔBDG）的增量与IVIG的BDG浓度相关（Spearmanr=0.59，p=0.02）。肾功能指标异常的患者在Ta1（403（207，484）pg/ml）时血清ΔBDG值高于肾功能正常的患者（172（85，316）pg/ml，p=0.036)。
结论：接受IVIG治疗的患者血清BDG值明显增高。BDG水平升高与IVIG的BDG含量和肾功能指标异常相关。
方法：本研究包括2021年10月至2022年10月住院期间接受IVIG输注的患者。我们随机检查了每位患者的两个IVIG样品。在九个时间点收集血清样品：前（Tpre），立即（T1-0），第一天后6h（T1-1）和12h（T1-2）；在IVIG输注期间，第二天立即（T2-0）和六小时后（T2-1），和IVIG输注后三天内（分别为Ta1，Ta2和Ta3）。采用Friedman检验进行统计分析。
结果：共有来自19例患者的159份血清BDG纳入分析。IVIG的BDG含量范围为249μg/ml至4812μg/ml。患者在T1-0时血清BDG显着升高（176（113，291）pg/ml，p=0.002）和Ta1（310（199，470）pg/ml，p<0.001)，与Tpre（41（38，65）pg/ml）相比。血清BDG（ΔBDG）的增量与IVIG的BDG浓度相关（Spearmanr=0.59，p=0.02）。肾功能指标异常的患者在Ta1（403（207，484）pg/ml）时血清ΔBDG值高于肾功能正常的患者（172（85，316）pg/ml，p=0.036)。
结论：接受IVIG治疗的患者血清BDG值明显增高。BDG水平升高与IVIG的BDG含量和肾功能指标异常相关。
